BACKGROUND: The positive effect of reperfusion after ST-elevation myocardial infarction (STEMI) can be reduced by ischemic/reperfusion (I/R) injury.Mannose-binding-lectin (MBL) and soluble C5b-9 (membrane-attack-complex) are involved in complement-driven cell lysis and may play a role in human myocardial I/R injury. We evaluated the potential association between MBL and sC5b-9 in plasma and subsequent cardiac dysfunction in patients with STEMI treated with primary percutaneous coronary intervention (pPCI). METHODS: The study included 74 STEMI-patients with acute occlusion of the left anterior descending coronary artery who were successfully treated with pPCI. Cardiac dysfunction was defined as left ventricular ejection fraction LVEF < 35%. RESULTS: Patients with subsequent LVEF < 35% had significantly higher median MBL and lower sC5b-9 compared to patients with LVEF > or = 35%. After adjustment of the multivariate logistic regression analysis, the odds for reduced LVEF was 5.5 (95% CI:1.5-19.3; p = 0.01) for patients with MBL > or = 800 mcg/L, and 5.0 (95% CI 1.4-18.4; p = 0.01) for patients with sC5b-9 < or = 160 mcg/L. CONCLUSION: High plasma MBL and low plasma sC5b-9 are independently associated with increased risk of cardiac dysfunction in STEMI patients treated with pPCI, probably due to increased complement activity during the ischemic and reperfusion process. The predictive value of low peripheral plasma sC5b-9 may be explained by an accumulation and activation of sC5b-9 in the infarcted myocardium.
BACKGROUND: The positive effect of reperfusion after ST-elevation myocardial infarction (STEMI) can be reduced by ischemic/reperfusion (I/R) injury.Mannose-binding-lectin (MBL) and soluble C5b-9 (membrane-attack-complex) are involved in complement-driven cell lysis and may play a role in human myocardial I/R injury. We evaluated the potential association between MBL and sC5b-9 in plasma and subsequent cardiac dysfunction in patients with STEMI treated with primary percutaneous coronary intervention (pPCI). METHODS: The study included 74 STEMI-patients with acute occlusion of the left anterior descending coronary artery who were successfully treated with pPCI. Cardiac dysfunction was defined as left ventricular ejection fraction LVEF < 35%. RESULTS:Patients with subsequent LVEF < 35% had significantly higher median MBL and lower sC5b-9 compared to patients with LVEF > or = 35%. After adjustment of the multivariate logistic regression analysis, the odds for reduced LVEF was 5.5 (95% CI:1.5-19.3; p = 0.01) for patients with MBL > or = 800 mcg/L, and 5.0 (95% CI 1.4-18.4; p = 0.01) for patients with sC5b-9 < or = 160 mcg/L. CONCLUSION: High plasma MBL and low plasma sC5b-9 are independently associated with increased risk of cardiac dysfunction in STEMI patients treated with pPCI, probably due to increased complement activity during the ischemic and reperfusion process. The predictive value of low peripheral plasma sC5b-9 may be explained by an accumulation and activation of sC5b-9 in the infarcted myocardium.
Authors: Nick S Laursen; Natasha Gordon; Stefan Hermans; Natalie Lorenz; Nicola Jackson; Bruce Wines; Edzard Spillner; Jesper B Christensen; Morten Jensen; Folmer Fredslund; Mette Bjerre; Lars Sottrup-Jensen; John D Fraser; Gregers R Andersen Journal: Proc Natl Acad Sci U S A Date: 2010-02-04 Impact factor: 11.205
Authors: C B Holt; J A Østergaard; S Thiel; T K Hansen; L Mellbin; P Sörensson; M Bjerre Journal: Clin Exp Immunol Date: 2019-06-03 Impact factor: 4.330
Authors: Mette Bjerre; Peter Holland-Fischer; Henning Grønbæk; Jan Frystyk; Troels K Hansen; Hendrik Vilstrup; Allan Flyvbjerg Journal: World J Hepatol Date: 2010-06-27
Authors: Ming Zhang; Yunfang Joan Hou; Erdal Cavusoglu; Daniel C Lee; Rudi Steffensen; Liming Yang; Daniel Bashari; Jose Villamil; Motaz Moussa; George Fernaine; Jens C Jensenius; Jonathan D Marmur; Wilson Ko; Ketan Shevde Journal: Int J Cardiol Date: 2011-12-15 Impact factor: 4.164